1 / 25

Supply Chain Changes A manufacturer’s perspective

Supply Chain Changes A manufacturer’s perspective. Mike Isles Andy Carr. MPI Associates Limited. Andrew Carr Associates Ltd. Two high level supply chain models. DTP. Reduced wholesaler. More accurately DTC ie “Direct to Customer” channel Retail Pharmacists Hospitals Dispensing Doctors

nishi
Télécharger la présentation

Supply Chain Changes A manufacturer’s perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supply Chain ChangesA manufacturer’s perspective Mike Isles Andy Carr

  2. MPI Associates Limited

  3. Andrew Carr Associates Ltd

  4. Two high level supply chain models DTP Reduced wholesaler • More accurately DTC • ie “Direct to Customer” channel • Retail Pharmacists • Hospitals • Dispensing Doctors • Selling to: • 14,000 customers (from eg 14) • Using “partners” to perform a range of distribution services • Sell product to a small number of wholesalers • Ownership of stock is still with wholesalers • Risks and rewards still owned by wholesalers • Commercial relationship with “customers” not owned by manufacturer • Downstream discounts determined by wholesalers There are benefits of both to manufacturers

  5. Supply Chain – Traditional method Manufacturer Control Outside Manufacturer Control ? % 12.5% disc ?% Manufacturer pre-wholesaler / own warehouse ~14 Wholesalers Patient Pharmacy ?% margin clawback Department of Health

  6. Supply Chain – Reduced wholesaling Manufacturer Control Outside Manufacturer Control ? % ?% disc ?% Manufacturer pre-wholesaler / own warehouse 2-3 Wholesalers Patient Pharmacy ?% margin clawback Department of Health

  7. Supply Chain – DTP Manufacturer Control Outside Manufacturer Control ? % Man. terms Manufacturer pre-wholesaler / own warehouse Agents/LSP Patient Pharmacy clawback Control & ownership move further down the Supply Chain Department of Health

  8. Manufacturers’ supply chain activity DTP Reduced Wholesalers • Pfizer (03/07) (U) • Astellas*(11/07) (U) • AstraZeneca (02/08) (A,U) • GSK (11/08) (A,U) • Lilly(07/09)(A,P) • Napp(10/07) (A,P,U) • sanofi aventis (11/07) (A,P,U) • Novartis (08/08) (A,U) • Roche (01/09) (A,U) • Janssen-Cilag(01/09) (A,P,U) • Novo Nordisk (03/09) (P,U) • UCB* (11/09)(A,P,U) • S & N (06/09) (A,P,U) • Bayer Schering(07/09)(A,P,U) • BMS(08/09) (A,U) • MSD (10/09) (A,P,U) • LEO Pharma (10/09) (A,P,U) A – AAH Pharmaceuticals Ltd P – Phoenix Healthcare Distribution U – Alliance Healthcare (Distribution) (Unichem) * Product specific arrangements

  9. Manufacturers’ supply chain partners A & U A & P P & U A, P, U U • Pfizer (03/07) • Astellas*(11/07) • GSK (11/08) • AstraZeneca (02/08) • Novartis (08/08) • Roche (01/09) • BMS(08/09) • Lilly(07/09) • Novo Nordisk (03/09) • Napp(10/07) • sanofi aventis (11/07) • Janssen-Cilag(01/09) • S & N (06/09) • Bayer Schering(07/09) • MSD(10/09) • LEO Pharma (10/09) • UCB (11/09) A – AAH Pharmaceuticals Ltd P – Phoenix Healthcare Distribution U – Alliance Healthcare (Distribution) (Unichem) DTP programs * Product specific arrangements

  10. Why are manufacturers changing?

  11. PPRS – direct impact on prices PPRS price reductions 1993 – 2.5% 1999 – 4.5% 2005 – 7.5% 2009 – 3.9% 2010 – 1.9% Manufacturers have seen an 18% reduction in the price of their medicines over 18 years, with a large patent expiry cliff-edge approaching in forthcoming years

  12. PPRS – impact of price cuts Pharma Manufacturers are exploring all avenues to mitigate the impact of price cuts

  13. Why are manufacturers changing?

  14. Supply and distribution legacies

  15. Efficiency savings in UK distribution

  16. Why are manufacturers changing?

  17. Partnership approach Simplification, focus, opportunities Opportunities Opportunities Supply partners Supply partners

  18. Win-win opportunities – Patient adherence/compliance

  19. Why are manufacturers changing?

  20. Increased visibility • Getting closer to the point of medicine delivery brings the following benefits for manufacturers: • End–to-end supply chain visibility • Reduction of product wastage • Commercial relationships with end contractors (pharmacists/D Doctors) • Reliable information on who is buying product • Management of increased demand

  21. Management of supply

  22. Why are manufacturers changing?

  23. Safety & security

  24. Summary

  25. Supply Chain ChangesA manufacturer’s perspective Mike Isles Andy Carr

More Related